Rapport Therapeutics, Inc Common Stock
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $720 |
Gross Profit | -252 | -244 | 360 | |
EBITDA | -26,669 | -29,244 | -26,864 | -23,261 |
EBIT | -26,925 | -29,496 | -27,108 | -23,521 |
Net Income | -26,925 | -26,732 | -24,063 | -19,980 |
Net Change In Cash | 0 | 0 | 0 | 720 |
Free Cash Flow | -17,599 | -25,092 | -20,528 | -14,672 |
Cash | 251,359 | 55,067 | 57,604 | 56,805 |
Basic Shares | 379,311 | 354,446 | 192,881 | 192,881 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 |
|---|---|---|
Revenue | $0 | $0 |
Gross Profit | -839 | -112 |
EBITDA | -77,468 | -34,664 |
EBIT | -78,307 | -34,776 |
Net Income | -78,307 | -34,786 |
Net Change In Cash | 0 | 0 |
Free Cash Flow | -67,233 | -28,817 |
Cash | 56,805 | 70,169 |
Basic Shares | 207,383 | 180,788 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$0.71 |
2025-06-30 | -$0.75 |
2025-03-31 | -$0.68 |
2024-12-31 | -$0.57 |
